Speaker Profile

Ph.D., CEO, GeneCentric Therapeutics

Dr. Milburn received his Ph.D. in Biophysical Chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Dr. Milburn has over 25 years of experience in biotech and pharmaceutical companies including over 20 years in senior management research positions. Dr. Milburn has published over 100 scientific articles on technology, research and development in the life sciences. At GeneCentric, Dr. Milburn is responsible for the RNA-based diagnostics development and commercialization.

Clinical Dx Showcase:
GeneCentric Therapeutics

GeneCentric develops and commercialize next generation oncology diagnostics and companion diagnostics built on RNA gene expression signatures in partnership with Biopharma companies and commercial reference labs.

Novel Oncology RNA-based Companion Diagnostics Development
RNA-based complementary and companion diagnostics could identify more patients able to receive clinical benefit from cancer therapeutics and increase response rates. RNA diagnostics better reflect the inherent expressed traits of a tumor, including genetic drivers and the immune environment.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6, June 28-30

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative